Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

181 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. van Oosterom AT, et al. Among authors: silberman s. Lancet. 2001 Oct 27;358(9291):1421-3. doi: 10.1016/s0140-6736(01)06535-7. Lancet. 2001. PMID: 11705489 Clinical Trial.
Imatinib: a targeted clinical drug development.
Capdeville R, Silberman S. Capdeville R, et al. Among authors: silberman s. Semin Hematol. 2003 Apr;40(2 Suppl 2):15-20. doi: 10.1053/shem.2003.50037. Semin Hematol. 2003. PMID: 12783370 Review.
Phase II study of imatinib in patients with small cell lung cancer.
Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, Kowalski MO, Sayles D, Dimitrijevic S, Fletcher C, Hornick J, Salgia R, Le Chevalier T. Johnson BE, et al. Among authors: silberman s. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5880-7. Clin Cancer Res. 2003. PMID: 14676110 Clinical Trial.
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. Heinrich MC, et al. Among authors: silberman s. J Clin Oncol. 2003 Dec 1;21(23):4342-9. doi: 10.1200/JCO.2003.04.190. J Clin Oncol. 2003. PMID: 14645423 Clinical Trial.
Management of malignant gastrointestinal stromal tumours.
Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Joensuu H, et al. Among authors: silberman s. Lancet Oncol. 2002 Nov;3(11):655-64. doi: 10.1016/s1470-2045(02)00899-9. Lancet Oncol. 2002. PMID: 12424067 Review.
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM. Apperley JF, et al. Among authors: silberman s. N Engl J Med. 2002 Aug 15;347(7):481-7. doi: 10.1056/NEJMoa020150. N Engl J Med. 2002. PMID: 12181402
Imatinib: the first 3 years.
Capdeville R, Silberman S, Dimitrijevic S. Capdeville R, et al. Among authors: silberman s. Eur J Cancer. 2002 Sep;38 Suppl 5:S77-82. doi: 10.1016/s0959-8049(02)80607-4. Eur J Cancer. 2002. PMID: 12528777 Review.
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Demetri GD, et al. Among authors: silberman sl. N Engl J Med. 2002 Aug 15;347(7):472-80. doi: 10.1056/NEJMoa020461. N Engl J Med. 2002. PMID: 12181401 Clinical Trial.
181 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page